Cargando…

In Vivo Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Murine Urinary Tract Infection Models

BACKGROUND: Cefiderocol (S-649266), a novel siderophore cephalosporin, shows potent activity against carbapenem-resistant Gram-negative bacilli. In the cefiderocol global surveillance study that focused on carbapenem-resistant Gram-negatives (SIDERO-CR-2014/2016), the most frequent bacterial species...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumoto, Shuhei, Kanazawa, Sachi, Nakamura, Rio, Tsuji, Masakatsu, Sato, Takafumi, Yamano, Yoshinori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630823/
http://dx.doi.org/10.1093/ofid/ofx163.1208
_version_ 1783269301760819200
author Matsumoto, Shuhei
Kanazawa, Sachi
Nakamura, Rio
Tsuji, Masakatsu
Sato, Takafumi
Yamano, Yoshinori
author_facet Matsumoto, Shuhei
Kanazawa, Sachi
Nakamura, Rio
Tsuji, Masakatsu
Sato, Takafumi
Yamano, Yoshinori
author_sort Matsumoto, Shuhei
collection PubMed
description BACKGROUND: Cefiderocol (S-649266), a novel siderophore cephalosporin, shows potent activity against carbapenem-resistant Gram-negative bacilli. In the cefiderocol global surveillance study that focused on carbapenem-resistant Gram-negatives (SIDERO-CR-2014/2016), the most frequent bacterial species recovered from patients with urinary tract infection (UTI) were K. pneumoniae and P. aeruginosa. The purpose of this study was to evaluate the in vivo efficacy of cefiderocol againt carbapenem-resistant K. pneumoniae and P. aeruginosain murine UTI models. METHODS: Cefiderocol, ceftazidime/avibactam (CZA), ceftolozane/tazobactam (C/T), meropenem (MEM) and cefepime (FEP) were used as the test compounds. Four test strains of E. coli EC-14, K. pneumoniae VA-357 harboring KPC-2, P. aeruginosa SR10163 (FEP-resistant strain), and NUBL-1122 harboring IMP-1 were used. MIC was determined by broth microdilution method. As recommended by CLSI, cefiderocol was tested in iron-depleted cation-adjusted Mueller Hinton broth. ICR female mice (n = 3–6) were infected by transurethral inoculation (ca. 2 × 10(5)CFU/mouse). Treatment was initiated 4, 10, 28, 34 hours post-infection. Viable cells in kidney tissue at 48 hours post-infection were counted. RESULTS: Against VA-357 (KPC-2), cefiderocol and CZA had the MICs of 1 and 2 μg/mL, respectively, and they showed ≥ 3-log(10)CFU from the initial therapy with 100 mg/kg treatment. These efficacy were superior to those of C/T, MEM and FEP at the same dose. Against NUBL-1122 (IMP-1), cefiderocol of 100 mg/kg significantly decreased the viable cells with ≥ 3-log(10)CFU (MIC, 1 μg/mL), while CZA, C/T, MEM and FEP did not show the bactericidal efficacy (MIC, ≥32 μg/mL). All the test compounds showed dose-dependent decrease in the viable cells in kidneys against ceftazidime-susceptible and -resistant strains of EC-14 and SR10163, respectively, in a reflection of their MICs. CONCLUSION: Cefiderocol exhibited in vivo bactericidal efficacy against carbapenem-resistant K. pneumoniae and P. aeruginosa in the UTI models, suggesting that cefiderocol is promising antibacterial agent for the treatment of cUTI infections caused by these resistant strains. DISCLOSURES: S. Matsumoto, SHIONOGI & CO., LTD.: Employee, Salary; S. Kanazawa, SHIONOGI & CO., LTD.: Employee, Salary; R. Nakamura, SHIONOGI & CO., LTD.: Employee, Salary; M. Tsuji, Shionogi & Co.: Employee, Salary; T. Sato, SHIONOGI & CO., LTD: Employee, Salary; Y. Yamano, SHIONOGI & CO., LTD.: Employee, Salary
format Online
Article
Text
id pubmed-5630823
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-56308232017-11-07 In Vivo Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Murine Urinary Tract Infection Models Matsumoto, Shuhei Kanazawa, Sachi Nakamura, Rio Tsuji, Masakatsu Sato, Takafumi Yamano, Yoshinori Open Forum Infect Dis Abstracts BACKGROUND: Cefiderocol (S-649266), a novel siderophore cephalosporin, shows potent activity against carbapenem-resistant Gram-negative bacilli. In the cefiderocol global surveillance study that focused on carbapenem-resistant Gram-negatives (SIDERO-CR-2014/2016), the most frequent bacterial species recovered from patients with urinary tract infection (UTI) were K. pneumoniae and P. aeruginosa. The purpose of this study was to evaluate the in vivo efficacy of cefiderocol againt carbapenem-resistant K. pneumoniae and P. aeruginosain murine UTI models. METHODS: Cefiderocol, ceftazidime/avibactam (CZA), ceftolozane/tazobactam (C/T), meropenem (MEM) and cefepime (FEP) were used as the test compounds. Four test strains of E. coli EC-14, K. pneumoniae VA-357 harboring KPC-2, P. aeruginosa SR10163 (FEP-resistant strain), and NUBL-1122 harboring IMP-1 were used. MIC was determined by broth microdilution method. As recommended by CLSI, cefiderocol was tested in iron-depleted cation-adjusted Mueller Hinton broth. ICR female mice (n = 3–6) were infected by transurethral inoculation (ca. 2 × 10(5)CFU/mouse). Treatment was initiated 4, 10, 28, 34 hours post-infection. Viable cells in kidney tissue at 48 hours post-infection were counted. RESULTS: Against VA-357 (KPC-2), cefiderocol and CZA had the MICs of 1 and 2 μg/mL, respectively, and they showed ≥ 3-log(10)CFU from the initial therapy with 100 mg/kg treatment. These efficacy were superior to those of C/T, MEM and FEP at the same dose. Against NUBL-1122 (IMP-1), cefiderocol of 100 mg/kg significantly decreased the viable cells with ≥ 3-log(10)CFU (MIC, 1 μg/mL), while CZA, C/T, MEM and FEP did not show the bactericidal efficacy (MIC, ≥32 μg/mL). All the test compounds showed dose-dependent decrease in the viable cells in kidneys against ceftazidime-susceptible and -resistant strains of EC-14 and SR10163, respectively, in a reflection of their MICs. CONCLUSION: Cefiderocol exhibited in vivo bactericidal efficacy against carbapenem-resistant K. pneumoniae and P. aeruginosa in the UTI models, suggesting that cefiderocol is promising antibacterial agent for the treatment of cUTI infections caused by these resistant strains. DISCLOSURES: S. Matsumoto, SHIONOGI & CO., LTD.: Employee, Salary; S. Kanazawa, SHIONOGI & CO., LTD.: Employee, Salary; R. Nakamura, SHIONOGI & CO., LTD.: Employee, Salary; M. Tsuji, Shionogi & Co.: Employee, Salary; T. Sato, SHIONOGI & CO., LTD: Employee, Salary; Y. Yamano, SHIONOGI & CO., LTD.: Employee, Salary Oxford University Press 2017-10-04 /pmc/articles/PMC5630823/ http://dx.doi.org/10.1093/ofid/ofx163.1208 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Matsumoto, Shuhei
Kanazawa, Sachi
Nakamura, Rio
Tsuji, Masakatsu
Sato, Takafumi
Yamano, Yoshinori
In Vivo Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Murine Urinary Tract Infection Models
title In Vivo Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Murine Urinary Tract Infection Models
title_full In Vivo Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Murine Urinary Tract Infection Models
title_fullStr In Vivo Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Murine Urinary Tract Infection Models
title_full_unstemmed In Vivo Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Murine Urinary Tract Infection Models
title_short In Vivo Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Murine Urinary Tract Infection Models
title_sort in vivo efficacy of cefiderocol against carbapenem-resistant gram-negative bacilli in murine urinary tract infection models
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630823/
http://dx.doi.org/10.1093/ofid/ofx163.1208
work_keys_str_mv AT matsumotoshuhei invivoefficacyofcefiderocolagainstcarbapenemresistantgramnegativebacilliinmurineurinarytractinfectionmodels
AT kanazawasachi invivoefficacyofcefiderocolagainstcarbapenemresistantgramnegativebacilliinmurineurinarytractinfectionmodels
AT nakamurario invivoefficacyofcefiderocolagainstcarbapenemresistantgramnegativebacilliinmurineurinarytractinfectionmodels
AT tsujimasakatsu invivoefficacyofcefiderocolagainstcarbapenemresistantgramnegativebacilliinmurineurinarytractinfectionmodels
AT satotakafumi invivoefficacyofcefiderocolagainstcarbapenemresistantgramnegativebacilliinmurineurinarytractinfectionmodels
AT yamanoyoshinori invivoefficacyofcefiderocolagainstcarbapenemresistantgramnegativebacilliinmurineurinarytractinfectionmodels